Details

Autor(en) / Beteiligte

• Takaura, Kenta
• Kurosaki, Masayuki
• Inada, Kento
• Kirino, Sakura
• Yamashita, Kouji
• Muto, Tomohiro
• Osawa, Leona
• Sekiguchi, Shuhei
• Hayakawa, Yuka
• Higuchi, Mayu
• Kaneko, Shun
• Maeyashiki, Chiaki
• Tamaki, Nobuharu
• Yasui, Yutaka
• Itakura, Jun
• Tsuchiya, Kaoru
• Nakanishi, Hiroyuki
• Takahashi, Yuka
• Izumi, Namiki
• Kanda, Tatsuo

Titel

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

Ist Teil von

• PloS one, 2022-02, Vol.17 (2), p.e0264075-e0264075

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The long-term prognosis of hepatocellular carcinoma (HCC) treated at a very-early-stage (the Barcelona Clinical Liver Cancer (BCLC) classification stage 0) was unclear, especially in terms of background liver disease. This single-center, retrospective study included 302 patients with BCLC stage 0 HCC treated with radiofrequency ablation (RFA) and followed for at least six months. We examined the impact of background liver disease on overall survival and recurrence. The median age was 72 (range; 36-91) years; the median tumor diameter was 15 (range; 8-20) mm. The etiologies of background liver disease were hepatitis B virus infection (HBV) in 24 cases, hepatitis C virus infection (HCV) in 195 cases, and non-viral (NBNC) in 83 cases. Among the patients with HCV, 63 had achieved sustained virological response (SVR) by antiviral therapy (HCV SVR) before developing HCC (n = 37) or after HCC treatment (n = 26), and 132 had active HCV infection (HCV non-SVR). The median overall survival was 85 (95% CI; 72-98) months, and the median recurrence-free survival was 26 (95% CI; 20-30) months. Active infection with hepatitis C virus negatively contributed to overall survival (HR 2.91, 95% CI 1.31-3.60, p = 0.003) and recurrence-free survival (HR 1.47, 95% CI 1.06-2.05, p = 0.011). The prognosis of RFA treatment for very early-stage HCC was favorable. Achieving SVR in hepatitis C was important for further prognosis improvement.